Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Affinity Asset Advisors, LLC

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Affinity Asset Advisors, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,073,517.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,073,517.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,073,517.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.6 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Michael Cho

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,073,517.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,073,517.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,073,517.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.6 %

12

Type of Reporting Person (See Instructions)

IN, HC

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Karyopharm Therapeutics Inc.

(b)

Address of issuer's principal executive offices:

85 Wells Avenue, 2nd Floor, Newton, Massachusetts, 02459

Item 2.

(a)

Name of person filing:

Affinity Asset Advisors, LLC Michael Cho

(b)

Address or principal business office or, if none, residence:

450 Park Avenue Suite 1403 New York, NY 10022

(c)

Citizenship:

Affinity Asset Advisors, LLC is a Delaware limited liability company, and Michael Cho is an individual and is a citizen of the United States.

(d)

Title of class of securities:

Common Stock, $0.0001 par value per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

The securities reported herein are directly held by Affinity Healthcare Fund, LP (the "Fund"). Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund and exercises voting and investment power over the securities held directly by the Fund reported herein pursuant to an investment management agreement between the Adviser, the Fund, and the general partner of the Fund. The Adviser may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund. Michael Cho, the managing member of the Adviser, may be deemed a beneficial owner of the securities reported herein held by the Fund. As of March 31, 2026, the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 2,073,517 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Karyopharm Therapeutics Inc. (the "Issuer"), which amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants (the "Warrants"). The Warrants are all subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of the shares issuable upon exercise of the Warrants (the "Beneficial Ownership Limitation").

(b)

Percent of class:

As of March 31, 2026, the Reporting Persons beneficially own 8.6% of the Common Stock outstanding. The percentages disclosed above are based on 24,116,833 shares of Common Stock of the Issuer outstanding as of March 30, 2026, consisting of (a) the 22,543,316 shares of Common Stock of the Issuer outstanding as of March 30, 2026, as set forth in the Issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 13, 2026, and (b) 1,573,517 shares of Common Stock issuable upon the exercise of Warrants held by the Fund. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

As of March 31, 2026, the Reporting Persons have sole power to vote or to direct the vote of 2,073,517 shares of Common Stock, which amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants after giving effect to the Beneficial Ownership Limitation.

(ii) Shared power to vote or to direct the vote:

As of March 31, 2026, the Reporting Persons have shared power to vote or to direct the vote of 0 shares of Common Stock.

(iii) Sole power to dispose or to direct the disposition of:

As of March 31, 2026, the Reporting Persons have sole power to dispose or to direct the disposition of 2,073,517 shares of Common Stock, which amount includes 1,573,517 shares of Common Stock issuable upon the exercise of warrants after giving effect to the Beneficial Ownership Limitation.

(iv) Shared power to dispose or to direct the disposition of:

As of March 31, 2026, the Reporting Persons have shared power to dispose or to direct the disposition of 0 shares of Common Stock.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Affinity Asset Advisors, LLC

Signature:	/s/ Andrew Weinstein
Name/Title:	Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
Date:	05/14/2026

Michael Cho

Signature:	/s/ Michael Cho
Name/Title:	Michael Cho, Self
Date:	05/14/2026

Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Affinity Asset Advisors, LLC

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed